Canada's Biotech Challenge

Canada has world-class biotech science. Too often, the companies built on it grow up somewhere else. Clarissa Desjardins, co-founder and CEO of Montreal’s Congruence Therapeutics, joins John Stackhouse on the state of biotech and what Canada must do to keep more of what it builds. In this episode: • How AI is changing the way new drugs are discovered • Why China’s rise is reshaping the global industry • Why biotech stays invisible in Canada, even to investors • What it would take to grow Canadian companies to global scale at home Chapters: 0:00 Will Canada's medicines come from China? 0:28 Biotech's missing place in Canada's agenda 1:32 From scientist to entrepreneur 3:47 Great science, too little commercialization 6:03 How AI is changing drug discovery 9:54 Why biotech is invisible, and underfunded 13:15 Health sovereignty and the anchor-company gap 18:33 China's rise in drug discovery 21:31 What Canada needs to do next 24:17 Closing thoughts CONNECT & SUBSCRIBE: • Follow RBC Thought Leadership on LinkedIn • Follow John Stackhouse on LinkedIn • For more insights visit RBC Thought Leadership Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.